< Back to previous page

Publication

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV

Journal Contribution - Journal Article

In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of AIDS. These compounds fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse transcriptase inhibitors (NtRTIs: tenofovir); non-nucleoside reverse transcriptase inhibitors (NNRTIs: nevirapine, delavirdine, efavirenz and etravirine); protease inhibitors (PIs: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir); cell entry inhibitors [fusion inhibitors (FIs: enfuvirtide) and co-receptor inhibitors (CRIs: maraviroc)]; and integrase inhibitors (INIs: raltegravir). These compounds should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development.
Journal: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
ISSN: 0924-8579
Issue: 4
Volume: 33
Pages: 307 - 20
Publication year:2009
BOF-keylabel:yes
IOF-keylabel:yes
BOF-publication weight:6
CSS-citation score:4
Authors from:Higher Education